

# New Hampshire Coronavirus Disease 2019 Weekly Partner Call

August 5, 2021

*Ben Chan  
Elizabeth Talbot  
Beth Daly  
Lindsay Pierce*

Thursday noon-time partner call will focus on science, medical, and vaccine updates with time for Q&A

# Thursday Noon-Time Partner Call Schedule

- After a 2 week break, we're back to weekly Thursday noon-time partner calls
- Webinar and call-in information will remain the same

# School and Childcare Partner Calls


- July 21<sup>st</sup>: Call to discuss CDC's update K-12 school and Childcare guidance
  - Presentation video and PPT slides are available:  
<https://www.covid19.nh.gov/resources/schools>
- August 11<sup>th</sup>: We will have another follow-up call with School and Childcare partners from 3:30-4:30
  - Call/webinar information are posted online:  
<https://www.covid19.nh.gov/resources/schools>

# Agenda

- Epidemiology update
- [MMWR publication](#): Large outbreak of SARS-CoV-2 in Provincetown, MA (Barnstable County)
- Review Delta variant vaccine effectiveness and talk about “Vaccine Breakthrough Infections”
- Questions & Answers (Q&A)


# Epidemiology Update

# U.S. National Daily Incidence of COVID-19



[https://covid.cdc.gov/covid-data-tracker/#trends\\_dailytrendscases](https://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases)

# Level of Community Transmission by State




Level of Community Transmission

high ● substantial ● moderate ● low ● no data ●

[https://covid.cdc.gov/covid-data-tracker/#cases\\_community](https://covid.cdc.gov/covid-data-tracker/#cases_community)


# Number of New COVID-19 Cases per Day in NH



<https://www.nh.gov/covid19/dashboard/overview.htm#dash>




# % of Tests (Antigen and PCR) Positive for COVID-19 (7-Day Average)




<https://www.nh.gov/covid19/dashboard/overview.htm#dash>

# Number of People Hospitalized with COVID-19 Each Day in NH (Hospital Census)



<https://www.nh.gov/covid19/dashboard/overview.htm#dash>

# Average Number of COVID-19 Deaths per Day in NH (Based on Date of Death)



<https://www.nh.gov/covid19/dashboard/overview.htm#dash>

# Level of Community Transmission in NH

Statewide  
Level of  
Transmission

**Moderate**


New Cases per 100k  
over 14 days

**95.5**

7-Day Total Test  
Positivity Rate

**3.9%**

- Minimal
- Moderate
- Substantial




Data as of: 8/4/2021

<https://www.covid19.nh.gov/dashboard/schools>

# Variant Proportions in the U.S.

United States: 4/25/2021 – 7/31/2021

United States: 7/18/2021 – 7/31/2021 NOWCAST



USA

WHO label	Lineage #	Type	%Total	95%PI
Alpha	B.1.1.7	VOC	2.9%	1.2-4.7%
Beta	B.1.351	VOC	0.0%	0.0-0.2%
Gamma	P.1	VOC	1.3%	0.2-2.5%
Delta	B.1.617.2	VOC	83.4%	79.6-87.0%
	AY.3	VOC	9.1%	6.2-12.0%
	AY.2	VOC	0.8%	0.0-1.7%
	AY.1	VOC	0.1%	0.0-0.5%
Epsilon	B.1.427	VOI	0.0%	0.0-0.2%
	B.1.429	VOI	0.0%	0.0-0.2%
Eta	B.1.525	VOI	0.0%	0.0-0.2%
Iota	B.1.526	VOI	0.2%	0.0-0.7%
	B.1.621		1.1%	0.2-2.2%
	B.1.621.1		0.6%	0.0-1.5%
	B.1.628		0.3%	0.0-1.0%
	B.1		0.1%	0.0-0.5%
	A.2.5		0.0%	0.0-0.2%
	Other*		0.0%	0.0-0.2%
	B.1.617.3	VOI	0.0%	0.0-0.2%
	B.1.626		0.0%	0.0-0.2%

\* Enumerated lineages are VOI/VOC or are circulating >1% in at least one HHS region during at least one two week period; remaining lineages are aggregated as "Other".

\*\* These data include Nowcast estimates, which are modeled projections that may differ from weighted estimates generated at later dates

# Sublineages of P.1 and B.1.351 (P.1.1, P.1.2, B.1.351.2, B.1.351.3) are aggregated with the parent lineage and included in parent lineage's proportion. AY.1, AY.2, and AY.3 are no longer aggregated with B.1.617.2.


Collection date, two weeks ending

SELECTED

<https://covid.cdc.gov/covid-data-tracker/#variant-proportions>

# Variant Proportions in the U.S.

United States: 7/18/2021 – 7/31/2021 NOWCAST



Updated Aug 3, 2021

Highlight Variant

# Variant Proportions in NH, 7/22 – 8/4 (Last 2 Weeks)

- 130 positive specimens were sequenced:
  - Alpha (B.1.1.7): 12 (9%)
  - Beta (B.1.351): 0 (0%)
  - Gamma (P.1): 1 (<1%)
  - Delta (B.1.617.2): 59 (45%)


# MMWR Publication



## Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021

- Context: “Independence Week” in Provincetown, MA (P-town), is a large tourist/party attraction; estimated 60,000+ attendees
  - Bad weather may have driven many “densely packed” parties indoors
- MMWR publication reports only on Massachusetts residents with COVID-19, but there are multiple other states affected
- 469 cases among MA residents (many more out-of-state cases)
  - 74% occurred in fully vaccinated persons
  - 90% of genetic sequencing showed Delta variant
  - Most were symptomatic (79% with vaccine breakthrough infection)
  - 5 hospitalizations, 0 deaths


**FIGURE 1. SARS-CoV-2 infections (N = 469) associated with large public gatherings, by date of specimen collection and vaccination status\* — Barnstable County, Massachusetts, July 2021**



# CT Values in Based on Vaccination Status

- Individual CT values are unable to be reported at the individual level (under federal lab regulations)
- At a population level, lower CT values are believed to represent higher viral loads/shedding
- This is an indirect measure of a person's potential ability to transmit infection; it remains unclear how CT values relate to transmission risk
- We have always said that anybody who is infected (even fully vaccinated people) have the potential to transmit to others; the risk may be greater with the Delta variant

FIGURE 2. SARS-CoV-2 real-time reverse transcription–polymerase chain reaction cycle threshold values\* for specimens from patients with infections associated with large public gatherings, by vaccination status<sup>†</sup> — Barnstable County, Massachusetts, July 2021<sup>§</sup>



# Vaccine Breakthrough (VBT) Infections

- We talk a lot about the % of infections that are due to VBT infections – that's probably not the right measure to be tracking (because it's misleading)
- The rate of infection in vaccinated vs. unvaccinated populations is a more appropriate measure
- % of VBT infections is affected by both vaccine efficacy AND the proportion of the population that is vaccinated
- As more people get vaccinated (i.e., as a higher % of the population is vaccinated), we expect that a greater % of infections will be in people who are fully vaccinated – that's NOT an indication of vaccine failure

# Field evaluation of vaccine efficacy\*

WALTER A. ORENSTEIN,<sup>1</sup> ROGER H. BERNIERI,<sup>2</sup>  
 JAMES S. MARKS,<sup>3</sup> KENNETH J. BART,<sup>1</sup> & BERNARD  
 J. COHEN<sup>4</sup>

*This paper describes the epidemic curve for measles vaccine, the efficacy of which is 70-80%. The methods are applicable to other vaccines and the techniques are indicated.*





Fig. 1. The relationship between the percentage of cases vaccinated (PCV) and the percentage of the population vaccinated (PPV) for seven different percentage values of vaccine efficacy (VE).

# Guidance on conducting vaccine effectiveness evaluations in the setting of new SARS-CoV-2 variants

**INTERIM GUIDANCE**  
22 JULY 2021

Addendum to Evaluation of vaccine effectiveness: Interim guidance

Example shown in figure with red diamond is the result for vaccine with 90% estimated VE and 90% PPV.



# Proportion of all COVID-19 cases expected to occur among people who were vaccinated

<b>Scenario</b>	<b>Vaccination coverage</b>	<b>Vaccine effectiveness</b>	<b>% of COVID-19 cases expected among vaccinated persons</b>
<b>1</b>	30%	70%	11%
<b>2</b>	50%	70%	23%
<b>3</b>	70%	70%	41%
<b>4</b>	90%	70%	73%
<b>5</b>	30%	90%	4%
<b>6</b>	50%	90%	9%
<b>7</b>	70%	90%	19%
<b>8</b>	90%	90%	47%

# Vaccine Effectiveness Against the Delta Variant



# Vaccine Effectiveness (VE) Against Delta Variant

Country	Study Link	COVID-19 Vaccine	VE at Preventing Infection*	VE at Preventing Severe Illness**
United Kingdom	<a href="#">Bernal et al. NEJM</a> ; <a href="#">Stowe et al. khub</a>	Pfizer-BioNTech	88%	
Canada	<a href="#">Nasreen et al. medRxiv</a>	Pfizer-BioNTech	85%	
Scotland	<a href="#">Sheikh et al. Lancet</a>	Pfizer-BioNTech	79%	
Israel	<a href="#">Press Release</a>	Pfizer-BioNTech	64%	

\* Includes preventing “confirmed infection” and “symptomatic infection”

\*\* Includes preventing hospitalizations and deaths (depending on study)

# Vaccine Effectiveness (VE) Against Delta Variant

Country	Study Link	COVID-19 Vaccine	VE at Preventing Infection*	VE at Preventing Severe Illness**
United Kingdom	<a href="#">Bernal et al. NEJM</a> ; <a href="#">Stowe et al. khub</a>	Pfizer-BioNTech	88%	96%
Canada	<a href="#">Nasreen et al. medRxiv</a>	Pfizer-BioNTech	85%	--
Scotland	<a href="#">Sheikh et al. Lancet</a>	Pfizer-BioNTech	79%	--
Israel	<a href="#">Press Release</a>	Pfizer-BioNTech	64%	93%

\* Includes preventing “confirmed infection” and “symptomatic infection”

\*\* Includes preventing hospitalizations and deaths (depending on study)

Preliminary estimates show that the Pfizer-BioNTech COVID-19 vaccine is:

- ~80% effective at preventing infection from the Delta variant
- >90% effective at preventing severe disease, including hospitalizations and deaths from COVID-19

# Vaccine Effectiveness (VE) Against Delta Variant

Country	Study Link	COVID-19 Vaccine	VE at Preventing Infection*	VE at Preventing Severe Illness**
United Kingdom	<a href="#">Bernal et al. NEJM</a> ; <a href="#">Stowe et al. khub</a>	Pfizer-BioNTech	88%	96%
		AstraZeneca	67%	92%
Canada	<a href="#">Nasreen et al. medRxiv</a>	Pfizer-BioNTech	85%	--
Scotland	<a href="#">Sheikh et al. Lancet</a>	Pfizer-BioNTech	79%	--
		AstraZeneca	60%	--
Israel	<a href="#">Press Release</a>	Pfizer-BioNTech	64%	93%

\* Includes preventing “confirmed infection” and “symptomatic infection”

\*\* Includes preventing hospitalizations and deaths (depending on study)

Preliminary estimates show that the Pfizer-BioNTech COVID-19 vaccine is:

- ~80% effective at preventing infection from the Delta variant
- >90% effective at preventing severe disease, including hospitalizations and deaths from COVID-19

# Summary

- COVID-19 is dramatically increasing in NH and across the U.S.
- Increases are largely being driven by Delta variant infections
  - Estimated to be ~2x more infectious compared to earlier circulating strains of SARS-CoV-2
  - Whether the Delta variant causes more severe disease is still being studied
- We need higher levels of vaccination to control this more infectious variant
- Vaccine breakthrough infections are expected/normal, especially as a greater proportion of the population gets vaccinated
- Current mRNA COVID-19 vaccines are still estimated to be ~80% effective at preventing infection from the Delta variant, but 90-95% effective at preventing severe disease

# Problem with Increasing Community Transmission

- Everybody has an increasing risk of exposure and infection
- People who are unvaccinated or only partially vaccinated are more likely to be infected and potentially have a severe outcome
- Fully vaccinated people are much less likely to develop infection and very unlikely to have a severe outcome if infected...
- But there will be more episodes of exposure to COVID-19... and the more exposure events, the greater the risk a fully vaccinated person might develop a vaccine breakthrough infection (no vaccine is 100% effective)
- Anybody who becomes infected has the potential to spread it to others in the community
- And the pandemic goes on...

# When Levels of Community Transmission are High, It's important for Everybody to Take Precautions

- The COVID-19 mitigation measures remain important:
  - Physical distancing
  - Avoiding high-risk settings for COVID-19 spread
  - Wearing facemasks in indoor public locations: this is especially important for people who are not fully vaccinated, have a weakened immune system, are at increased risk for severe disease, or who have a household member who is unvaccinated or at increased risk of severe COVID-19
  - Getting tested for any new symptoms of COVID-19; a list of currently available testing locations is available online:  
<https://www.dhhs.nh.gov/dphs/cdcs/covid19/documents/covid-testing-options.pdf>
- Vaccination is the most important thing people can do to protect themselves, their families, and their communities

# Vaccination Is the Most Important Intervention

- Anybody who is not yet vaccinated against COVID-19 should get vaccinated
  - Vaccination is very safe and protective against infection, helps prevent the spread of COVID-19, and dramatically reduces a person's risk for severe disease if they develop COVID-19
- Anybody who has only gotten one vaccine dose of a 2-dose series (Pfizer or Moderna vaccines) needs to complete the vaccination series to have the highest level of protection, especially against the Delta variant
  - People can go to [www.vaccines.gov](http://www.vaccines.gov) to find a nearby location to be vaccinated

# Continue to Use These Resources

- [Isolation Guide](#): For people diagnosed with COVID-19 (*unchanged*)
- [Quarantine Guide](#): For household close contacts who are NOT fully vaccinated (*minor updates*)
- [Observation Guide](#): For non-household close contacts (e.g., close contact with someone with COVID-19 in the community), and for fully vaccinated household contacts (*substantial updates*)



# Continue to Use These Resources

New Hampshire  
**COVID-19 RESPONSE**

Home Resources FAQ News Mental Health Resources Industry Best Practices

## COVID-19 NEW HAMPSHIRE

GET VACCINATED GET TESTED

I TESTED POSITIVE FOR COVID-19 I WAS EXPOSED TO COVID-19

INTERACTIVE DASHBOARDS

New Hampshire announced **138 cases** for August 4. There were an average of **123 cases per day** over the most recent 7-day period (July 29 to August 4). This is a **96% increase** compared to the previous 7-day period.

	<b>101,277</b> Total Cases		<b>53.7%</b> Fully Vaccinated		<b>3.9%</b> 7-Day Test Positivity		<b>34</b> Current Hosp.
	<b>893</b> Active Cases		<b>58.5%</b> At Least 1 Dose		<b>3,507</b> Avg. Daily Tests		<b>1,389</b> Total Deaths


<https://www.covid19.nh.gov/>

# Thursday Noon-Time Partner Call Schedule

- After a 2 week break, we're back to weekly Thursday noon-time partner calls
- Webinar and call-in information will remain the same

# School and Childcare Partner Calls

- July 21<sup>st</sup>: Call to discuss CDC's update K-12 school and Childcare guidance
  - Presentation video and PPT slides are available:  
<https://www.covid19.nh.gov/resources/schools>
- August 11<sup>th</sup>: We will have another follow-up call with School and Childcare partners from 3:30-4:30
  - Call/webinar information are posted online:  
<https://www.covid19.nh.gov/resources/schools>



# New Hampshire Coronavirus Disease 2019 Weekly Partner Call

August 5, 2021

*Ben Chan  
Elizabeth Talbot  
Beth Daly  
Lindsay Pierce*

Thursday noon-time partner call will focus on science, medical, and vaccine updates with time for Q&A